Efficacy and safety of intravenous amiodarone for short-term treatment of paroxysmal supraventricular tachycardia in children.
The use of intravenous amiodarone was assessed during 23 episodes of paroxysmal supraventricular tachycardia in 15 children aged 9 days to 11 years. Five of the fifteen patients had congenital structural heart disease, and three had Wolf-Parkinson-White syndrome. Tachyarrhythmias were returned to sinus rhythm during 20 of the 23 episodes (87%). No major adverse effects occurred. Recurrence of tachycardia was not observed during short-term follow-up. In conclusion, intravenous amiodarone is an effective, safe antiarrhythmic drug for short-term treatment of supraventricular tachycardia in children.
Soult
J A
JA
Department of Pediatrics, Virgen Rocio Children's Hospital, Seville University School of Medicine, Spain.
Muñoz
M
M
Lopez
J D
JD
Romero
A
A
Santos
J
J
Tovaruela
A
A
D000638:Amiodarone / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006330:Heart Defects, Congenital / Q000150:complications; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007262:Infusions, Intravenous; D008297:Male; D013614:Tachycardia, Paroxysmal / Q000150:complications / Q000188:drug therapy*; D013617:Tachycardia, Supraventricular / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome; D014927:Wolff-Parkinson-White Syndrome / Q000150:complications
D000638:Amiodarone